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The Restoring Invisible and Abandoned Trials (RIAT) initiative is an internationaleffort concerned with two fundamental problems in the scientific literature on
clinical trials: many trials are inaccurately or incompletely reported in journal publica-
tions and not all trials conducted are even published. RIAT aims to address these
problems by offering a methodology that allows other people to responsibly correct
the record (1).
We are writing with concerns about inaccurate and incomplete reporting in a trial
published in Clinical and Vaccine Immunology, as well as ethical concerns about the
informed consent process.
In their study of quadrivalent human papillomavirus vaccine (NCT00092482) (2), the
authors stated that they conducted a “placebo-controlled” trial. However, control arm
participants did not receive a “placebo” or an “inactive solution,” the descriptions
provided in the informed consent forms for this trial. Instead, they received an injection
containing amorphous aluminum hydroxyphosphate sulfate (AAHS), a proprietary ad-
juvant added to enhance immune response (3). The use of the term “placebo” to
describe an active and reactogenic comparator like AAHS inaccurately describes the
formulation that the control arm received and may also have obscured an accurate
assessment of vaccine safety. Further, the publication does not report the rationale for
the selection of AAHS control, an important omission that constitutes underreporting
of important methodological details.
According to the manufacturer’s clinical study report for this trial, the rationale for
selecting AAHS adjuvant as the control was as follows:
“Aluminum adjuvant was chosen as the appropriate control for the qHPV vaccine for the
following reasons:
The inclusion of aluminum adjuvant in both vaccine and placebo preserved the blinding of
the study because it allowed the vaccine and placebo to be visually indistinguishable; and
The safety profile of Merck’s aluminum adjuvant is well characterised. On the other hand,
the safety profile of the HPV 6, 11, 16 and 18 L1 VLPs required further evaluation in
humans. By using placebo that contained a dose of aluminum adjuvant that was identical to
the dose included in the qHPV vaccine, it was possible to assess the safety profile attributable
to the HPV 6, 11, 16 and 18 L1 VLP component of the vaccine” (3).
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Thus, the manufacturer’s stated rationale for selecting AAHS as a control (to
characterize the safety of human papillomavirus [HPV]-like particles) lacks clinical
relevance, and a nonplacebo control may have obscured an accurate assessment of
quadrivalent HPV vaccine safety (3). We have documented all of these issues
elsewhere (3).
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